Clinical Trial Update: Efficacy and Safety of Encaleret Compared to Standard of Care in Participants With ADH1 [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating the efficacy and safety of Encaleret versus standard of care in Autosomal Dominant Hypocalcemia (ADH1). The study status is Active…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Hypocalcemia

Drugs mentioned

• Encaleret (encaleret)

Snippet

Sponsor: Calcilytix Therapeutics, Inc., a BridgeBio company | Conditions: Autosomal Dominant Hypocalcemia (ADH) | Phase 3 | Status: ACTIVE_NOT_RECRUITING